Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 104Bevacizumab 98Oxaliplatin 97Capecitabine 96Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 63Injections 62Fluorouracil 62sintilimab 57anlotinib 53Surgical Procedures, Operative 50130-nm albumin-bound paclitaxel 50Docetaxel 49fludarabine 46Pemetrexed 45Standard of Care 43venetoclax 42Leucovorin 42Biopsy 42Irinotecan 41lenvatinib 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × CIMAvax EGF × Clear all
NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Not yet recruiting
29 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡